Cyclic peptides sit in a fascinating place in drug discovery: larger than classical small molecules, smaller than antibodies, and engineered to hit targets that neither can reach. Cyclization — closing the peptide backbone or side chains into a ring — transforms a floppy, protease-vulnerable chain into a rigid, stable macrocycle that can survive in serum, bind its target with sub-nanomolar affinity, and in some cases even cross membranes orally. This is why cyclic peptides have become one of the most productive scaffolds in modern medicinal chemistry.
This deep-dive covers the chemistry of cyclization (head-to-tail, side chain, bicyclic, stapled), why it dramatically improves stability and affinity, the natural cyclic peptides that inspired the field (cyclosporine, oxytocin, cyclotides), and the platforms — Aileron's stapled peptides, BicycleTx's bicycles, and Ra Pharma's Zilucoplan — that are bringing macrocycles into the clinic. Cyclic peptides are the primary way medicinal chemists are exploring the "beyond rule of five" drug space.
What Are Cyclic Peptides?
Cyclic peptides are peptides in which the linear chain has been chemically closed into a ring, either by joining the N- and C-termini (head-to-tail), by bridging two side chains, by linking a side chain to a terminus, or by forming more complex bicyclic or polycyclic architectures. The defining feature is a topological constraint: the backbone is no longer free to sample all conformations.
Cyclization matters for four reasons:
- Proteolytic resistance. Exopeptidases need free termini; endopeptidases prefer extended, flexible substrates. Cyclic peptides resist both.
- Conformational rigidity. A locked conformation pays a smaller entropic penalty on binding, boosting affinity (often 10–1000×).
- Improved membrane permeability. Intramolecular hydrogen bonds hide polar groups inside the macrocycle, reducing effective polar surface area — the basis of cyclosporine's oral bioavailability.
- Beyond rule of five targets. Flat protein-protein interaction surfaces that are undruggable by small molecules can be engaged by rigid macrocyclic peptides.
Natural cyclic peptides
Nature has been making cyclic peptides for billions of years. Familiar examples:
- Cyclosporine A — 11-residue cyclic undecapeptide from the fungus Tolypocladium inflatum, immunosuppressant, orally bioavailable despite 1,203 Da mass.
- Oxytocin and vasopressin — 9-residue peptides with a disulfide bridge forming a 6-residue ring plus a 3-residue tail.
- Vancomycin — a glycopeptide antibiotic with a tricyclic peptide core.
- Cyclotides — plant-derived ~30-residue peptides with a head-to-tail cyclic backbone and three disulfide bonds (cyclic cystine knot), extraordinary stability.
- Gramicidin S, tyrocidine, actinomycin — classic antibiotic cyclic peptides.
Mechanism: Types of Cyclization
Cyclic peptides are classified by how the ring is closed. The four main classes:
| Cyclization type | Chemistry | Examples |
|---|---|---|
| Head-to-tail | C-terminal carboxyl + N-terminal amine → amide | Cyclosporine, gramicidin S |
| Side chain to side chain | Disulfide, lactam (Lys–Glu), or triazole (click) | Stapled peptides, oxytocin (S–S) |
| Side chain to terminus | Lactam, thioether | Desmopressin, some cyclotides |
| Bicyclic / polycyclic | Multiple linkers on a scaffold | BicycleTx platform, cyclotides |
Stapled peptides
Stapled peptides, developed in the lab of Gregory Verdine at Harvard (Schafmeister et al., 2000, JACS; Walensky et al., 2004, Science), use an all-hydrocarbon crosslink between two non-natural amino acids inserted one or two helical turns apart. The staple locks an α-helix in its bound conformation, dramatically boosting affinity for α-helix-recognizing targets — especially intracellular protein-protein interactions like MDM2/p53 and BCL-2 family members.
Why the α-helix matters: roughly 40% of protein-protein interfaces involve α-helical recognition. Small molecules rarely mimic these surfaces well, and linear peptides don't stay helical in water. Stapling forces helicity, stabilizes against proteases, and — remarkably — often enables cell entry.
ALRN-6924 (Aileron Therapeutics) was the clinical archetype: a stapled peptide designed to disrupt the MDM2/MDMX–p53 interaction, reactivating p53 tumor suppressor function in wild-type p53 cancers. It advanced through Phase 1/2 trials in hematologic malignancies and chemoprotection settings, showing proof-of-concept for cell-penetrant stapled peptides — though clinical development has had setbacks.
Bicyclic peptides
Bicyclic peptides take the stability-through-constraint idea one step further by using two separate macrocyclic rings sharing a common scaffold. The platform pioneered by Bicycle Therapeutics (co-founded by Sir Greg Winter, Nobel laureate in Chemistry 2018) uses a trivalent small-molecule scaffold (TATA, 1,3,5-tris(bromomethyl)benzene) to crosslink three cysteines in a phage-displayed library, creating a vast diversity of bicyclic shapes.
Bicycles combine the target-specificity and selectivity of an antibody with the tissue penetration, fast clearance, and synthetic accessibility of a small molecule. Zelenectide pevedotin (BT8009), a Bicycle Toxin Conjugate targeting Nectin-4, has shown clinical activity in urothelial cancer — an important clinical validation of the platform.
Ra Pharma and zilucoplan
Zilucoplan (originally from Ra Pharmaceuticals, acquired by UCB) is a synthetic macrocyclic peptide inhibitor of complement component C5, approved in 2023 for generalized myasthenia gravis. Its 15-residue macrocyclic structure and lipid chain enable once-daily subcutaneous self-administration — an important real-world advantage over the infused antibody eculizumab targeting the same pathway. It is one of the clearest clinical proofs that cyclic peptides can compete head-to-head with monoclonal antibodies on efficacy while offering a much better administration profile.
Clinical and Experimental Evidence
Cyclosporine: the prototype
Cyclosporine (Borel et al., 1976, Agents and Actions) is the founding story of cyclic peptide drugs. It is orally bioavailable (~30%) despite having molecular weight 1,203 Da — far above the classical Lipinski "rule of five" cutoff of 500 Da. The reason: intramolecular hydrogen bonds shield its polar amide groups, giving it an effective "chameleonic" behavior — polar enough to solubilize, lipophilic enough to cross membranes. Cyclosporine made organ transplantation routine and set the paradigm for "beyond rule of five" drugs.
Stapled peptides in the clinic
Beyond ALRN-6924, stapled peptides targeting WNT/β-catenin, estrogen receptor, and KRAS have entered preclinical and early clinical development. Results have been mixed — cell permeability is difficult to predict, and some early clinical failures have tempered enthusiasm — but the chemistry is now well-established as a medicinal chemistry tool.
Bicycle therapeutics pipeline
Bicycle's platform has generated multiple clinical candidates including Nectin-4-targeted bicycle toxin conjugates (BT8009/zelenectide pevedotin), MT1-MMP targeted bicycles, and tumor-targeted immune agonists. Phase 1/2 data have shown meaningful objective responses in heavily pretreated solid tumor patients.
Cyclotides as scaffolds
Cyclotides — ultra-stable plant cyclic peptides with a cystine-knot topology — are being explored as delivery scaffolds in which bioactive sequences can be grafted into the structural backbone, inheriting the cyclotide's extraordinary stability. Oral bioavailability and protease resistance are exceptional; the challenge is making them hit arbitrary targets.
Applications and Use Cases
- Protein–protein interaction inhibitors — MDM2/p53, BCL-2 family, β-catenin, KRAS. Classical "undruggable" targets.
- GPCR agonists/antagonists — oxytocin, vasopressin, GLP-1 analogs (semaglutide incorporates a small lipidation-loop element).
- Antibiotic peptides — polymyxins, daptomycin (cyclic lipopeptide), vancomycin.
- Imaging agents and radiotheranostics — DOTATATE (cyclic somatostatin analog) for neuroendocrine tumors.
- Immunomodulators — cyclosporine, tacrolimus family.
- Toxin conjugates — Bicycle's approach of a cyclic peptide homing warhead plus a cytotoxic payload.
Connection to Gene Editing
Cyclic peptides and gene editing intersect in several useful ways.
First, cyclic peptide inhibitors of DNA-repair and editing enzymes are valuable tools for CRISPR research. Selective inhibitors of DNA-PK or 53BP1 can push repair pathway choice toward homology-directed repair (HDR), improving precise editing efficiency. Rigid cyclic peptide scaffolds can engage flat protein surfaces that small molecules miss.
Second, cell-penetrating cyclic peptides are being investigated as delivery vehicles for gene-editing cargo. Some cyclic peptides (e.g., cyclic poly-arginine derivatives) enter cells much more efficiently than their linear counterparts, raising the possibility of cyclic-peptide-tagged ribonucleoproteins or base editors.
Third, stapled peptides that modulate transcription factors overlap conceptually with epigenetic reprogramming. If you can bias a transcription factor like p53, β-catenin, or even OCT4 with a cell-penetrant macrocycle, you are doing something philosophically similar to transient epigenetic reprogramming. For the biology of that approach, see our companion piece on Yamanaka factor peptide delivery and our epigenetic clocks article.
Finally, both fields share the beyond rule of five design philosophy: traditional drug-likeness rules were built around small molecules. CRISPR components, stapled peptides, bicycles, and LNP-delivered cargos all violate classical rules — and all are transforming medicine anyway.
Limitations and Open Questions
- Permeability remains unpredictable. Not every stapled or cyclized peptide becomes cell-permeable; the chameleonic behavior of cyclosporine is rare and hard to engineer rationally.
- Manufacturing. Cyclization steps add cost and complexity to SPPS workflows. Head-to-tail cyclization in particular is prone to dimerization and epimerization.
- IP and scaffold diversity. The field leans heavily on a few workhorse scaffolds (hydrocarbon staples, TATA-bicycles, cystine knots). Expanding scaffold diversity is an active area.
- Clinical translation. Despite beautiful in vitro data, stapled peptides in particular have had mixed clinical outcomes. Understanding which sequences become truly bioavailable is not yet a solved science.
Frequently Asked Questions
Why are cyclic peptides more stable than linear ones?
Because cyclization removes the free N- and C-termini that exopeptidases attack, enforces rigid conformations that endopeptidases do not recognize, and locks the peptide into protease-resistant shapes. The result is often orders-of-magnitude longer half-life in serum.
What is a stapled peptide?
A peptide whose α-helical conformation has been locked by a covalent "staple" — usually a hydrocarbon crosslink between two non-natural amino acids inserted one helical turn apart. Pioneered in Gregory Verdine's lab, stapled peptides can penetrate cells and engage intracellular protein-protein interactions that small molecules can't reach.
How do cyclic peptides cross membranes if peptides usually can't?
The canonical explanation is intramolecular hydrogen bonding that shields polar amide groups, creating a "chameleonic" molecule that is polar in water but exposes a lipophilic face in membranes. Cyclosporine is the textbook case. The phenomenon is not universal — it depends on sequence, conformation, and solvent.
What is the "beyond rule of five" drug space?
Christopher Lipinski's rule of five defined classical small-molecule drug-likeness. Many important protein-protein interactions can't be engaged by molecules that obey those rules. "Beyond rule of five" drugs — cyclic peptides, macrocycles, PROTACs, stapled peptides — deliberately violate those constraints to hit previously undruggable targets.
Are cyclic peptides always natural?
No. Natural cyclic peptides (cyclosporine, vancomycin, cyclotides) inspired the field, but most therapeutic candidates today are fully synthetic macrocycles designed through medicinal chemistry, phage display, or computational design.
What makes bicyclic peptides different from regular cyclics?
Bicyclic peptides have two fused rings sharing a common scaffold, giving them more constrained topology and often higher affinity and selectivity. Bicycle Therapeutics uses a trivalent small-molecule scaffold to crosslink three cysteines, generating vast diverse libraries via phage display.
